Medivation snaps up BioMarin's late-stage breast cancer med in $410M-plus deal

Lots of companies are working to bulk up in the cancer field--but not BioMarin ($BMRN). Buckling down on rare diseases, the company is out-licensing its Phase III PARP inhibitor to Medivation ($MDVN) for $410 million up front, with another $160 million in milestones. The prospect--talazoparib--entered Phase III back in 2013 for advanced breast cancer among patients with BRCA 1 or BRCA 2 mutations, and Medivation is hoping to add it to a marketed portfolio that already includes the successful prostate cancer pill Xtandi. More

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.